Is Inhibitor Therapeutics, stock a buy?
What Is The Conclusion?
Right now our advanced algorithms say:
Do the analyst corps agree?
Interesting Questions and Easy Answers!
We cannot find any recorded dividends paid in our systems.
Sorry, we do not have any analyst data for this ticker
We cannot find data for Inhibitor Therapeutics, 10 years ago, but if you had invested on Monday 9th of September 2019 when the price was $0.0650, you would have made a profit of $0.0040 per share or 6.15%
No, the average daily trading liquidity for Inhibitor Therapeutics, is $10 703 thousand. Trading in stocks with this little trading liquidity is very dangerous, and you can get into a situation where it will be hard to trade your stocks. In addition, these types of stocks usually have very high volatility.
Inhibitor Therapeutics, has no real debt, which is good in periods of high inflation. With a high cash flow to debt ratio of 1.03, the company's ability to pay off the debt is good. The company is still not profitable, and high inflation will make it harder to become profitable as costs increase and consumer spending decreases.
We have calculated the inflation risk for Inhibitor Therapeutics, to be low [0.3 of 1]
US inflation for July 2024 was 0.15%. Over the last 12 months, the US inflation is 2.92%. The 10-year treasury yield that indicates the future interest level is currently 3.72 and is down -0.95 over the last 30 days.